Mild SLE Without Renal Involvement When Hydroxychloroquine Has Not Achieved Disease Control

This protocol covers the next treatment step for patients with mild, non-renal systemic lupus erythematosus who remain above the target disease activity threshold despite hydroxychloroquine — used alone or together with glucocorticoids.

Clinical Scenario

Mild SLE without renal involvement, characterised by:

Constitutional symptoms or mild arthritis
Rash affecting ≤9% of body surface area
Platelet count 50–100 × 10&sup9;/L
SLEDAI ≤6
BILAG C, or no more than one BILAG B manifestation

Prior Treatment — Insufficient Response

The previous treatment line — hydroxychloroquine, alone or combined with glucocorticoids — did not achieve the target outcome: a SLEDAI score of 0 (remission) or SLEDAI ≤4 (low disease activity state). This protocol describes the step taken after that inadequate response.

Next-Step Treatment Approach (Partial Overview)

For patients who have not responded adequately to hydroxychloroquine, the protocol involves consideration of adding an immunomodulating or immunosuppressive agent. The specific agent selection, criteria, and complete regimen are available in the full structured protocol.

Treatment Goals

SLEDAI score of 0 (remission) or SLEDAI ≤4 (low disease activity state).

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2023-224762

Mild disease: constitutional symptoms; mild arthritis; rash ≤9% body surface area; platelet count (PLTs) 50–100 × 10&sup9;/L; SLEDAI≤6; BILAG C or ≤1 BILAG B manifestation.

In patients not responding to hydroxychloroquine (alone or in combination with glucocorticoids) or patients unable to reduce glucocorticoids below doses acceptable for chronic use, addition of immunomodulating/immunosuppressive agents (eg, methotrexate (1b/B), azathioprine (2b/C) or mycophenolate (2a/B)) and/or biological agents (eg, belimumab (1a/A) or anifrolumab (1a/A)) should be considered.

View source ↗